Skip to main content
Clinical Trials/IRCT20190711044175N1
IRCT20190711044175N1RecruitingPhase 1

Cell therapy using human endometrial stem cell(hEnSCs) in patients with Secondary progressive-MS(SPMS): Phase I clinical trial

Tehran University of Medical Sciences0 sites10 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 1
Status
Recruiting
Enrollment
10

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to 45 years (—)
Sex
Female

Inclusion Criteria

  • (1)Women with SPMS who did not respond to their disease-modifying therapies .
  • (2) Age between 18–45 years
  • (3) EDSS less than 5.5
  • (4) Disease duration of 2 - 15 years..
  • (5) Women with at least one delivery
  • (6) Women who are taking Rituximab drugs

Exclusion Criteria

  • Women under the age of 18 and over 45 years
  • Pregnant patients
  • Patients with positive results from screening tests for hepatitis B and C, human immunode?ciency virus (HIV), and human T-cell lymphotropic virus (HTLV) were also excluded from the study.
  • Patients who had used cytotoxic agents or hormonal therapy within 3 months prior to the study .
  • Patients with endometriosis and other uterine problems

Investigators

Similar Trials